IMM vs. OKYO, AOR, OBI, OPTI, OBD, HEMO, ONC, RLM, NSCI, and SNG
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include OKYO Pharma (OKYO), AorTech International (AOR), Ondine Biomedical (OBI), OptiBiotix Health (OPTI), Oxford BioDynamics (OBD), Hemogenyx Pharmaceuticals (HEMO), Oncimmune (ONC), Realm Therapeutics (RLM), NetScientific (NSCI), and Synairgen (SNG). These companies are all part of the "biotechnology" industry.
OKYO Pharma (LON:OKYO) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.
ImmuPharma's return on equity of -163.24% beat OKYO Pharma's return on equity.
18.1% of ImmuPharma shares are owned by institutional investors. 31.9% of OKYO Pharma shares are owned by insiders. Comparatively, 42.8% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, ImmuPharma had 4 more articles in the media than OKYO Pharma. MarketBeat recorded 4 mentions for ImmuPharma and 0 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.00 beat ImmuPharma's score of -0.15 indicating that OKYO Pharma is being referred to more favorably in the media.
ImmuPharma has higher revenue and earnings than OKYO Pharma. ImmuPharma is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.
ImmuPharma received 259 more outperform votes than OKYO Pharma when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 63.64% of users gave OKYO Pharma an outperform vote.
OKYO Pharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.
Summary
ImmuPharma beats OKYO Pharma on 10 of the 12 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
Free IMM Stock Alerts